Open Drug Discovery Center for Alzheimer's Disease

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: ALLAN I LEVEY
Organization: EMORY UNIVERSITY
Fiscal Year: 2022
Award: $848,837
Funding agency: National Institute on Aging

The Open Drug Discovery Center for AD (Open-AD) Structural Biology core aims to provide
Target Enabling Packages (TEPs): a combination of experimental tools and knowledge that will
allow researchers to investigate the biology of potential drug targets and to test therapeutic
hypotheses. The TEPs will consist of: gene knockout reagents and cell lines; purified target
proteins for functional studies and for the development of antibodies and inhibitors; and
structures of proteins and protein:ligand complexes, to understand protein functions and support
drug development. Target selection and the definition of the required experimental tools will be
determined in consultation with the Bioinformatics and the Admin and Data Cores, which will
bring in community expertise. The Structural Biology core will have a central role within the
Open-AD project, providing purified proteins for assay development and screening by the
Assay core and structural data to guide chemical development by the MedChem core. By
releasing all reagents and data, we will enable and promote deeper and wider study by the
biomedical research community. The Structural Biology core team is already engaged in active
collaboration with the Mangravite and Levey groups, generating TEPs for targets discovered in
the AMP-AD consortium; some of these TEPs will form the basis of the first chemical
development programs within the new proposed Open-AD project.

Terms: <AD dementia><Address><Alzheimer><Alzheimer Type Dementia><Alzheimer disease><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease dementia><Alzheimers Dementia><Alzheimers disease><Antibodies><Assay><Attention><Automobile Driving><Binding><Bio-Informatics><Bioassay><Bioinformatics><Biologic Assays><Biological><Biological Assay><Biology><Biomedical Research><CARD3><CARDIAK><CD44><CD44 gene><Cell Body><Cell Line><CellLine><Cells><Chemicals><Collaborations><Communities><Complex><Consultations><Crystallization><Data><Development><Diamond><Disease><Disorder><Drug Targeting><Ensure><Enzyme Gene><Enzymes><Foundations><Funding><Generations><Genes><Human><Human Biology><Individual><Integral Membrane Protein><Intervention><Intervention Strategies><Intrinsic Membrane Protein><Investigators><Knock-out><Knockout><Knowledge><Lead><Ligand Binding><Ligands><Link><MDU3><Modern Man><Molecular Interaction><Pb element><Pgp1><Physiologic><Physiological><Pilot Projects><Primary Senile Degenerative Dementia><Program Development><Proteins><RIP2><RIPK2><RIPK2 gene><Reagent><Reproducibility><Research><Research Personnel><Research Resources><Researchers><Resolution><Resources><Role><Route><Scientist><Site><Strains Cell Lines><Structure><Synchrotrons><System><Testing><Time><Transmembrane Protein><Transmembrane Protein Gene><Validation><Work><antibody inhibitor><assay development><base><biologic><cultured cell line><dementia of the Alzheimer type><developmental><driving><drug development><drug discovery><experiment><experimental research><experimental study><heavy metal Pb><heavy metal lead><interventional strategy><knockout gene><membrane-organizing extension spike protein><moesin><peer><pilot study><primary degenerative dementia><protein complex><protein function><reconstitute><reconstitution><screening><senile dementia of the Alzheimer type><small molecule><social role><structural biology><therapeutic evaluation><therapeutic testing><tool>